Fig. 1: Identification of the candidate FGFs-related genes in pathological myocardial hypertrophy.

a–c The results were from the analysis of the GSE18801 dataset. a The corresponding FGFs of the 5 genes correlated with the physiological and pathological myocardial hypertrophy were visualized by the heatmap in the normal, swim, and isoproterenol (ISO) treatment samples. The darker shade of red or blue represents the higher correlation level. b Venn diagram visualizing the myocardial hypertrophy-related differentially expressed genes between swim and ISO treatment. c KEGG enrichment analysis of the influence of pathological myocardial hypertrophy genes after ISO treatment. The y-axis refers to pathway terms. The x-axis is the rich factor. d A profile of the mRNA expression of FGFs in Sham or transverse aortic constriction (TAC)-operated mouse heart at 6 weeks. Heatmap depicts differentially expressed FGFs mRNA in Sham and TAC heart samples (n = 4/group). Two-tailed student’s t-test. e Real-time quantitative PCR assays were performed to determine the mRNA levels of FGF18 in neonatal rat cardiomyocytes (NRCMs). n = 5. Data represent means ± SD. Two-tailed student’s t-test. f Real-time quantitative PCR assays were performed to determine the mRNA levels of FGF18 in Sham or TAC mice. n = 5. Data represent means ± SD. Two-tailed student’s t-test. g Representative western blots; Quantitative results of FGF18 protein expression in NRCMs and neonatal rat cardiac broblasts (NRCFs) treated with ISO for 48 h. n = 5. Data represent means ± SD. Two-tailed student’s t-test. All numbers (n) are biologically independent experiments. Source data are provided as a Source data file.